Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed cases of SARS-CoV-2 infection hospitalized in reference services identified by the Ministry of Health and Social Action of Senegal~* Adults (≥18 years)~* Full understanding and consent to participate to the trial~* No contraindications to taking the tested treatments~* Clinical status from 3 to 5 on the seven-category ordinal scale~* Pneumonia highlighted by infiltration of the lungs by chest CT scan or chest radiography~* Absence of contraindications to radiographic examinations (X-ray and/or CT scan) for diagnosis and/or follow-up~* Inclusion in the 72 hours following the radiological pneumonia confirmation~Non-inclusion Criteria:~* Pregnant or breastfeeding woman~* Patient at high risk of death within 3 days of inclusion, in the clinician's opinion~* Corrected QT interval (QTc) \>500ms~* Heart electrical dysfunction: atrioventricular block Mobitz type II second-degree, high-grade or complete without a functioning pacemaker~* Uncontrolled and clinically significant heart diseases, such as arrhythmia, angina or decompensated congestive heart failure~* Kidney failure (Cl \< 30 mL/min)~* Patients with liver cirrhosis whose Child-Puch score is B or C~* Patients who have liver disease abnormalities with ALT or AST \> 5 times ULN~* Patients who have a known HIV status~* Patients who have other clinically-important diseases in decompensation which may interfere with the evaluation or completion of the tested treatment's procedure, in the clinician's opinion~* Patients with a clinical or psychological condition which, in the clinician's opinion, does not allow adequate evaluation of the tested treatment~* Known allergy to the studied treatment regimen~* Other contraindications with the studied treatment regimen~* Known drug-drug interaction with a treatment usually taken by the participant contraindicating one of the studied treatment regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.
- Standard of Care + Nafamostat mesilate (Type: EXPERIMENTAL): * The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.~* Nafamostat mesilate

Based on this trial design, predict the completion outcome and termination type (if applicable).